Immunomodulatory drug treats psoriasis by a new mechanism: the selective deactivation of TYK2 through its catalytically defective domain, the pseudokinase.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
12 January 2023
In the version of this article initially published online, the reported status of Nimbus Therapeutics’ drug candidate NDI-034858 was incomplete and has now been updated, and the number of trial participants corrected to 259 people from 250. The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. TYK2-blocking agent showcases power of atypical kinase. Nat Biotechnol 40, 1701–1704 (2022). https://doi.org/10.1038/s41587-022-01602-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01602-w
